Powder: -20°C for 3 years | In solvent: -80°C for 2 years
PD 089828 is a competitive inhibitor of the receptor Tyrosine Kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM)
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 263.00 | |
50 mg | In stock | $ 393.00 | |
100 mg | In stock | $ 576.00 | |
500 mg | In stock | $ 1,220.00 |
Description | PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM) |
Targets&IC50 | EGFR:5.47 µM , PDGFRβ:1.76 µM , FGFR1:0.15 µM |
In vitro | PD 089828 as a novel, broadly active protein tyrosine kinase inhibitor with long-lasting but reversible cellular effects.?The potential therapeutic use of these broadly acting, nonselective inhibitors as antiproliferative and antimigratory agents could extend to such diseases as cancer, atherosclerosis and restenosis in which redundancies in growth-signaling pathways are known to exist. |
Molecular Weight | 405.28 |
Formula | C18H18Cl2N6O |
CAS No. | 179343-17-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 2.5 mM
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD-089828 179343-17-0 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors FGFR EGFR Src PDGFR ATP nonselective PD 089828 autophosphorylation PD089828 HER1 Epidermal growth factor receptor ErbB-1 phosphorylation vascular antiproliferative smooth antimigratory competitive Inhibitor Platelet-derived growth factor receptor muscle cells inhibit Fibroblast growth factor receptor inhibitor